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Abstract This prospective open-label pilot study evaluated
the effectiveness and safety of adalimumab and the
relationship to antibodies against infliximab (IFX) in adult
patients with active rheumatoid arthritis (RA) who had been
treated previously with IFX and experienced treatment
failure owing to lack or loss of response or intolerance.
Patients self-administered adalimumab 40 mg subcutane-
ously every other week for 16 weeks, followed by
maintenance therapy for up to Week 56. Measures of
effectiveness included American College of Rheumatology
(ACR) and European League Against Rheumatism
(EULAR) response criteria, 28-joint Disease Activity
Score, and the Health Assessment Questionnaire Disability
Index. Serum IFX concentrations, human antichimeric
antibody against IFX (HACA), adalimumab serum concen-
trations, antiadalimumab antibody, and safety also were
assessed. Of the 41 enrolled patients, 37 completed
16 weeks and 30 completed 56 weeks of treatment. Patients
experienced clinically meaningful improvements in all
measures of RA activity, with greater response rates
observed for patients who had experienced loss of initial
response to or intolerance of IFX. At Week 16, 46% of
patients achieved an ACR20 and 28% achieved an ACR50;
61% achieved an at least moderate and 17% achieved a
good EULAR response. Clinical benefit was maintained
through Week 56 in all effectiveness parameters. Baseline
HACA status did not significantly impact effectiveness. No
new safety signals were observed; neither former IFX
intolerance status nor baseline HACA status had a clinically
relevant impact on adverse event frequency or severity.
Adalimumab was effective and well-tolerated in patients
with RA who previously failed IFX therapy, irrespective of
reason for discontinuation and of HACA status.
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Introduction
Although tumor necrosis factor (TNF) antagonists are
highly effective agents for the treatment of rheumatoid
arthritis (RA), a subset of patients with RA may be
intolerant to one of these agents or may experience an
inadequate response or a loss of response over time [1–8].
A relevant clinical question, particularly as non-anti-TNF
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biologics have become available for RA therapy, is whether
switching to a different TNF antagonist would be effective
when the first has failed or resulted in intolerance [9].
Clinical reports to date demonstrated that a switch from one
TNF antagonist to another is safe and effective [10–23].
Failure in effectiveness is recommended to be specified as
an initial lack of response or loss of an initial response over
time [16]. The formation of antibodies against infliximab
(IFX) has been found to reduce the effectiveness of IFX
over time [24].
This pilot study investigated the effectiveness and safety
of adalimumab in patients with RA who had been treated
previously with IFX and experienced treatment failure
owing to no response, loss of response, or intolerance.
The impact of anti-IFX antibodies on the subsequent
therapy with adalimumab was also examined.
Materials and methods
Patients
This prospective open-label study included men and
women ≥18 years of age who met the American College
of Rheumatology (ACR) criteria for the diagnosis of RA for
at least 6 months, had active RA as defined by the 28-joint
Disease Activity Score (DAS28) ≥3.2 at study entry, and
had previous use of IFX defined as administration of at
least four infusions. The reasons for discontinuation of IFX
were collected as no response, loss of response, or
intolerance (i.e., infusion reactions) based on the inves-
tigator’s assessment. Patients who discontinued IFX owing
to adverse reactions other than intolerance were not allowed
to enter the study. Additional exclusion criteria encom-
passed prior treatment with alkylating agents, intravenous
immunoglobulin, or any investigational agent within
30 days or five half-lives (whichever was longer); IFX
within the last 8 weeks; more than one disease-modifying
antirheumatic drug (DMARD) or DMARD combination
after IFX treatment; biologic RA therapies other than IFX;
total lymphoid irradiation; history of malignancies; inflam-
matory joint disease other than RA; uncontrolled medical
conditions (e.g., diabetes and congestive heart failure);
active tuberculosis (TB), histoplasmosis, listeriosis, positive
serology for hepatitis B or C, or human immunodeficiency
virus; persistent infection or severe infection requiring
hospitalization or recent treatment with intravenous or oral
antibiotics; previous diagnosis or signs of central nervous
demyelinating diseases; pregnancy; or breastfeeding.
If patients had chest radiographs indicative of prior TB
infection or a positive purified protein derivative (PPD)
tuberculin skin test, appropriate prophylactic anti-TB
therapy had to be initiated before entering the study.
The protocol was approved by an independent ethics
committee at participating sites, and written informed
consent was obtained from all patients.
Study design
This was a 16-week open-label study that was followed by
maintenance therapy for up to 56 weeks. After a screening
period of at least 3 days (to allow for assessment of the
PPD tuberculin skin test administered at the study entry
visit), all patients self-administered adalimumab 40 mg
subcutaneously every other week (eow) in addition to their
pre-existing antirheumatic therapy. Doses of DMARDs,
glucocorticoids (prednisone equivalent ≤10 mg/day), and/or
nonsteroidal anti-inflammatory drugs that patients may
have been taking at study entry were to remain stable until
Week 16. Patients were to be withdrawn from the study if
they did not show adequate response to study treatment at
Week 16 (less than 20% reduction in tender joint count [TJC]
and/or swollen joint count [SJC] compared with study entry).
Addition of further DMARDs was not allowed.
Effectiveness, pharmacokinetic, and safety evaluations
Patients were assessed at screening, and then at baseline,
Weeks 2, 8, and 16, and every 8 weeks thereafter through
Week 56. Effectiveness assessments included the change in
DAS28 compared with study entry and both European
League Against Rheumatism (EULAR) and ACR response
criteria, the Health Assessment Questionnaire Disability
Index (HAQ DI), and acute-phase reactants. The effective-
ness results of Week 16 were considered primary.
Adverse events (AEs) were collected at each visit after
the first adalimumab injection up to 70 days after the last
injection.
Serum concentrations of adalimumab were analyzed at
baseline and at Weeks 16, 40, and 56 using a validated
enzyme-linked immunosorbent assay (ELISA) method by
Abbott Laboratories. The lower limit of quantitation
(LLOQ) for adalimumab was established at 31.3 ng/ml in
undiluted serum. Antiadalimumab antibody (AAA) was
measured at study entry and at Weeks 16, 40, and 56 using
a validated double-antigen ELISA. The LLOQ for AAA
was established at 5 ng/ml in undiluted serum. A positive
antiadalimumab signal was defined as a concentration
exceeding 20 ng/ml that could not be suppressed by
≥50% after the addition of 10% human serum to the
sample. Human antichimeric antibody (HACA; i.e., anti-
IFX antibodies) and serum IFX concentrations status were
determined at baseline using ELISA methods. Because the
presence of adalimumab interferes with the serum IFX
ELISA assay, HACA and serum IFX concentrations were
not assessed beyond baseline.
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Statistical analysis
The sample size of this open-label pilot study was based on
practical rather than biometric considerations. Both the
effectiveness and safety analyses were performed on the set
of patients who received at least one injection of adalimu-
mab. Subgroup analyses for effectiveness endpoints also
were performed by reason for discontinuation of IFX and
by HACA status at baseline. In the case of discontinuation
of IFX owing to no response or loss of response, patients
were counted in the corresponding group regardless of
whether they had an additional cause of intolerance,
whereas the IFX discontinuation owing to intolerance
subgroup was exclusive.
Effectiveness analysis consisted of summary statistics and
confidence intervals with last-observation-carried-forward
methods applied. Pharmacokinetic analysis consisted of
descriptive statistics.
Results
Patient disposition and baseline characteristics
Of 41 patients enrolled in the study, 37 (90.2%) completed
16 weeks of treatment. A total of 30 patients (73.2%) were
still receiving adalimumab at the Week-56 visit. Of the 11
patients who withdrew from the study before Week 56, six
(14.6%) withdrew owing to the occurrence of one or more
AEs and seven (17.1%) withdrew owing to a lack of
effectiveness (more than one reason for discontinuation was
possible).
The majority of patients were white (95%) and female
(88%), with a mean age of 55 years. The mean duration of
RA for all treated patients was 12 years, and the mean/
median duration of prior IFX treatment was 17/13 months.
The mean (standard deviation) period between the last IFX
infusion and first adalimumab administration was 13±
5.3 weeks, with a median of 11 weeks. A total of 19
patients had received their last IFX infusion more than
12 weeks before the first adalimumab injection. Table 1
summarizes the demographic and RA disease character-
istics for the study population, by reason of discontinuation
of IFX and by HACA status.
A total of 27 (66%) patients were receiving DMARDs at
baseline, with methotrexate being the most common (25
patients). Measurable serum HACA concentrations were
found in 17 of 41 (41.5%) patients at baseline. Nine
patients were not assessable for HACA status owing to
remaining IFX serum concentrations. Each of these nine
patients had discontinued therapy because of unsatisfactory
response (either no response or loss of response). The
pattern of reasons for discontinuation of IFX was somewhat
variable, with six (40%) of 15 patients who were HACA
negative experiencing no response to IFX compared with
four (23.5%) of 17 patients who were HACA positive
experiencing no response to IFX (Table 2).
A total of six (14.6%) patients received isoniazid prophy-
laxis for TB based on baseline chest radiograph indicative of
latent TB, positive PPD skin test, or other risk factors.
Table 1 Disease severity characteristics and prior infliximab/DMARD administration by reason for discontinuation of prior infliximab and
HACA status













Mean duration of RA, y 11.6±7.4 12.2±9.2 11.8±7.0 9.2±2.5 9.6±4.5 15.4±9.1
Current use of 1 DMARD, n (%) 27 (66) 10 (67) 14 (67) 3 (60) 9 (53) 11 (73)
Mean duration of infliximab treatment, mo 17.3±15.1 9.3±5.3 23.4±17.6 15.6±14.0 12.8±8.8 20.2±18.6
Mean dose per infliximab infusion, mg 262.4±87.6 263.7±81.9 267.5±100.0 237.2±47.8 279.6±81.5 264.3±111.2
Mean interval last infliximab/first adalimumab, week 13.0±5.3 13.4±5.2 11.9±5.1 16.4±5.8 14.9±6.2 12.0±4.8
DAS28 6.1±0.9 5.9±0.7 6.2±1.0 6.5±0.9 6.3±0.9 6.1±0.9
Tender joint count (28 joints) 14.8±6.6 13.7±6.9 14.7±6.6 18.6±4.7 14.6±6.6 14.6±7.2
Swollen joint count (28 joints) 8.2±4.8 5.9±4.1 9.0±4.6 12.0±4.4 9.7±4.4 8.5±5.5
HAQ DI 1.85±0.49 1.92±0.52 1.80±0.43 1.85±0.71 1.89±0.50 1.79±0.48
CRP, mg/l 25.1±32.0 23.3±26.8 26.3±38.1 26.0±21.4 29.2±28.8 29.3±40.5
CRP C-reactive protein; DAS28 28-joint Disease Activity Score; DMARD disease-modifying antirheumatic drug; HACA human antichimeric
(anti-infliximab) antibody; HAQ DI Health Assessment Questionnaire Disability Index; RA rheumatoid arthritis
aMean±SD except where otherwise specified.
b Not assessable in nine patients because of the presence of infliximab serum concentrations.
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Effectiveness
All patients
Clinically meaningful improvements occurred in all
measures of RA activity in the overall patient popula-
tion after 16 weeks of adalimumab treatment (Table 3).
The ACR and EULAR response rates were maintained or
increased through 56 weeks (Fig. 1). Similarly, the
DAS28, the HAQ DI, TJC, SJC, and C-reactive protein
(CRP) concentrations improved from baseline to Week 16
(Table 3).
Table 2 Baseline HACA status and infliximab serum concentration status by reason for discontinuation of prior infliximab
Reason for discontinuation of prior infliximab HACA statusa Measurable infliximab serum concentration at study entry
Positive (n=17) Negative (n=15) Yes (n=9) No (n=32)
No response 4 6 4 10
Loss of response 10 7 5 17
Intolerance 3 2 0 5
HACA human antichimeric (anti-infliximab) antibody
a In nine patients, HACA could not be determined because of measurable infliximab serum concentrations (see second column from right).
Table 3 Adalimumab efficacy at week 16 (LOCF data)
All patientsa
(N=41)











ACR20 response, % 46 29 60 40 47 43
ACR50 response, % 28 14 40 20 47 7
ACR70 response, % 13 7 20 0 18 7
Moderate EULAR response, % 61 47 67 80 53 53
Good EULAR response, % 17 7 24 20 24 7
DAS28, mean change from baseline
Absolute change±SD −1.5±1.6 −1.0±0.9 −1.8±2.0 −1.4±0.6 −1.6±1.8 −1.1±1.6
Percent change −23 –16 −28 −23 −25 −17
DAS28 mean value 4.6 4. 9 4.4 5.0 4.7
HAQ DI score (0–3),
mean change from baseline
Absolute change ± SD −0.21±0.50 −0.13±0.53 −0.36±0.48 −0.15±0.34 −0.36±0.52 −0.08±0.43
Percent change −11 −7.5 −20 −5 −18 −3
HAQ DI mean value 1.64 1.79 1.42 1.70 1.53 1.88
Tender joint count (0–28 joints),
mean change from baseline
Absolute change±SD −6.8±8.3 −5.1±4.6 −7.2±10.6 −10.0±5.7 −7.2±9.3 −5.6±8.8
Percent change −38 −36 −37 −54 −40 −30
Swollen joint count (0–28 joints),
mean change from baseline
Absolute change ± SD −4.6±5.1 −2.9±2.7 −6.1±5.0 −7.8±4.7 −5.5±4.8 −4.2±6.6
Percent change −53 −47 −65 −60 −48 −48
CRP (mg/l), mean change from baseline
Absolute change ± SD −3.8±19.5 −5.4±18.8 −1.1±21.3 −10.6±13.3 −6.3±22.4 −0.8±18.7
Percent change −21 −15 −40 −40 −17 −34
ACR American College of Rheumatology; DAS28 28-joint Disease Activity Score; EULAR European League Against Rheumatism; HACA human
antichimeric antibody (anti-infliximab); HAQ DI Health Assessment Questionnaire Disability Index; CRP C-reactive protein (reference 4 mg/l)
a Total number of patients enrolled; last observation carried forward (LOCF).
b Those patients who had discontinued prior infliximab treatment for both an efficacy and safety reason were assigned to the corresponding
efficacy subgroup. The intolerance subgroup consists of patients who had discontinued prior infliximab treatment strictly because of intolerance.
c Nine patients were not assessable for HACA owing to measurable infliximab concentrations.
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Effectiveness by reason for discontinuation of prior IFX
therapy
Adalimumab treatment led to clinically relevant improve-
ment in disease activity irrespective of the reason for
stopping prior IFX therapy. However, the intolerance group
was small, which limits the relevance of the results. At
Week 16, ACR20 was 29%, 60%, and 40% among those
patients who had no response, loss of response, and
intolerance to IFX, respectively (Table 3). By Week 56,
an increase in response rates was found across all subsets
(Fig. 1a). At Week 16, a moderate EULAR response was
achieved by 47%, 67%, and 80% of patients who had no
response, a loss of response, and intolerance to IFX,
respectively (Table 3). The rates of moderate EULAR
response increased in all subsets through Week 56. A good
EULAR response was achieved at Week 16 by 7%, 24%,
and 20% of patients with no response, loss of response, and
intolerance, respectively. The rates of patients with good
EULAR response increased up to Week 56 (Fig. 1b). The
DAS28 and the HAQ DI improved from baseline in all
three subgroups at all time points evaluated, with the
greatest response occurring in those patients who had
stopped IFX owing to loss of response (Week 16 data
shown in Table 3).
All three subgroups experienced improvements from
baseline in both TJC and SJC at all time points measured,
with those who reported intolerance to IFX or loss of
response achieving a slightly greater benefit compared with
those who had no response to IFX (Table 3). A similar
pattern of relative change was found for the reduction of
CRP concentrations (Table 3).
Effectiveness by HACA status
At 16 weeks, a total of 47% of HACA-positive patients and
43% of HACA-negative patients achieved an ACR20
response, whereas 47% and 7% of these patient subgroups,
respectively, achieved an ACR50 response (Table 3).
Similarly, 53% of HACA-positive patients and 53% of
HACA-negative patients achieved a moderate EULAR
response at 16 weeks (Table 3). Both HACA-positive and
HACA-negative patients achieved clinically important
mean changes in other measures of disease activity,
including TJC and SJC, DAS28, and HAQ DI (Table 3).
The response rates markedly increased continuously from
Week 24 (not shown) up to Week 56 in patients with
negative HACA status at baseline and were sustained in
patients with positive HACA status (Fig. 2).
Pharmacokinetics
From Weeks 17 to 45 of the study, eight of 41 patients
(19.5%) switched to 40 mg weekly administration of





























Fig. 2 American College of Rheumatology 20% (ACR20), ACR50,
ACR70 response and European League Against Rheumatism
(EULAR) response rates to adalimumab treatment at Week 56 (last
observation carried forward) by human antichimeric (anti-infliximab)
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Fig. 1 a American College of Rheumatology 20% (ACR20), ACR50,
and ACR70 responses and b European League Against Rheumatism
(EULAR) responses with adalimumab treatment at Week 56 (last
observation carried forward) by reason for discontinuation of prior
infliximab
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request. Twelve of 14 (86%) patients receiving adalimumab
40 mg eow without concomitant DMARD and 21 of 25
patients (84%) receiving adalimumab 40 mg eow with
methotrexate remained on the original dose regimen for the
duration of the study. The summary statistics of serum
adalimumab concentrations for patients remaining on the
original dosage are provided in Table 4. Mean serum trough
adalimumab concentrations in these patients were within or
slightly above the 4- to 8-μg/ml range, which is the typical
trough concentration for the recommended regimen of
adalimumab 40 mg eow [25]. For patients with measurable
HACA at baseline, mean serum adalimumab trough
concentrations ranged from 1 to 4 µg/ml, which is lower
than those achieved in patients without measurable HACA
levels and below the typical trough concentration for 40 mg
eow (data not shown). As noted earlier (see “Effectiveness
by HACA status”), baseline HACA status did not appear to
have a major impact on effectiveness outcome parameters.
Two patients (4.9%, both of whom had measurable HACA
concentrations at baseline) developed AAA and both
responded well to adalimumab (both without concomitant
DMARD treatment), with a DAS28 change from baseline
to Week 56 of −1.5 in one patient (AAA present at Week 16
only, despite weekly adalimumab injections beyond
Week 16) and of −5.4 in the other patient (AAA present
at Weeks 40 and 56, with no dose increase of adalimumab).
Safety
Overall, 43 events were reported by 34 patients during
47 weeks of mean exposure to adalimumab (37 patient–
years), the most frequent being RA or nasopharyngitis.
Neither former IFX intolerance status nor baseline HACA
status appeared to have a clinically meaningful impact on
the frequency or severity of allergic reactions or other AEs.
No demyelinating disorders or other autoimmune disorders,
including lupus-like reactions, were reported. One patient
with a history of hypertension died during the study as a
result of intracerebral bleeding. This event was considered
to be probably unrelated to study drug by the investigator.
One patient developed pulmonary TB during the study
period. Approximately 6 months after study entry, the
patient developed dry cough; 5 additional months later, TB
was diagnosed based on a positive polymerase chain
reaction of the sputum. At screening, the patient, who had
contact with a person with active TB 10 years before, had
no abnormalities in the chest X-ray and a negative PPD test
result. Although night sweats and cough had occurred
during the former IFX treatment as well, TB was not
diagnosed at that time. The event resolved after 9 months of
anti-TB therapy. One other serious infection (cellulitis) was
reported. Two patients reported the development of lym-
phomas (one large B cell lymphoma after three injections of
adalimumab, one T cell lymphoma after 1 year of
adalimumab treatment in a patient with RA and Sjögren’s
disease) during the study. Both events were considered
either unrelated or probably unrelated to study drug
administration by the investigator owing to the short
exposure to adalimumab, the history of previous exposure
to other immunosuppressive agents, and the underlying RA.
Coincidentally, one of the two lymphoma cases occurred in
the same patient who was diagnosed with TB.
Discussion
In accordance with other reports about successful switching
from one TNF antagonist to another, the results of this study
indicate that patients with RAwho had previously discontinued
treatment with IFX experienced clinically meaningful improve-
Table 4 Summary statistics of serum adalimumab concentrations (µg/ml) for patients remaining on the original dose regimen (40 mg every other
week; N=33)
Week
Without methotrexate With methotrexate
Baselinea Week 16 Week 56 Baselinea Week 16 Week 56
N 12 10 5 21 19 17
Mean – 4.3 7.2 – 6.3 7.1
SD – 4.0 5.9 – 3.6 3.9
Minimum – 0.0 0.0 – 0.4 0.0
Median – 3.1 5.0 – 5.8 7.6
Maximum – 10.6 13.6 – 14.6 12.6
CV% – 93.6 81.1 – 56.7 54.4
CV Coefficient of variation
a For nine patients who had measurable infliximab results at baseline, baseline adalimumab concentrations were not included in the summary
statistics because there is potential for infliximab to interfere with the adalimumab assay.
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ments in all effectiveness endpoints with adalimumab treatment
[10–15, 17–19]. The patients who reported a loss of response
under IFX treatment appeared to experience the greatest
effectiveness with adalimumab by several disease-response
measures, followed by the small patient subset that had been
intolerant to IFX. The patients with no response to their
previous IFX therapy had somewhat lower response rates to
adalimumab. Similar results were recently published in
another open-label study in a large patient cohort who
switched from prior anti-TNF therapy to adalimumab [18].
The documentation of reason for discontinuation of IFX is
limited, as there was no other criterion but the investigator’s
clinical assessment.
Interestingly, patients with a reported initial lack of
response to IFX had the lowest mean DAS28 value and
lowest joint counts at baseline among the subsets by reason
of IFX discontinuation, whereas the mean HAQ DI at
baseline was worst in these patients. However, most of the
recent publications either from registers or from clinical
studies on switching among TNF antagonists are based on
the physician’s discretion when the reasons for discontin-
uation are reported [17–19].
Results of subgroup analyses by patient’s baseline
HACA status (available for 32 of the 41 patients) indicate
that adalimumab is effective and well-tolerated in patients
who may have developed HACA with prior IFX treatment.
The low ACR50 and ACR70 and good EULAR response
rates at Week 16 in patients with negative HACA appear to
be more likely related to confounding baseline character-
istics, such as a greater percentage of patients who had
experienced no response to IFX and a longer RA duration
compared with patients with positive HACA status.
However, beyond Week 16, the response rates in the
HACA-negative subset increased and even surpassed the
rates achieved by HACA-positive patients.
Results of the pharmacokinetic analysis indicate that, for
the majority of patients, the mean steady-state serum
adalimumab trough concentrations achieved with the
recommended regimen of 40 mg eow were near or above
4 to 8 µg/ml, which is consistent with what has been
observed in other pharmacokinetic trials of adalimumab in
patients with RA [26, 27]. These concentrations are three to
seven times the average effective concentration in 50% of
patients for TJC, SJC, and numeric ACR [27]. Although
mean serum adalimumab trough concentrations appeared to
be lower in patients with measurable HACA at baseline, the
potential for interference of HACA with the serum
adalimumab assay has not been evaluated. In general, the
mean and median serum adalimumab concentrations were
greater in patients who concomitantly received methotrex-
ate. In a recent study in 121 patients with RA treated with
adalimumab, good responders had greater adalimumab
serum concentrations than nonresponders, and the forma-
tion of AAA (present in 21/121) was reduced in patients
who received concomitant methotrexate [28]. AAAs were
detected in two of the patients in this analysis, both were
not receiving concomitant DMARDs and both had a
positive HACA status at study entry. In previous clinical
adalimumab trials, AAA had been documented in 12% of
the patients and was not found to have an impact on the
efficacy of adalimumab [29].
Adalimumab was generally well-tolerated in this selected
population, and safety results did not suggest any new signals
with regard to the safety of the drug. In particular, no
additional risks for allergic reactions under adalimumab were
found in these 41 patients with a history of intolerance to IFX.
In the two patients diagnosed with lymphomas (cutane-
ous T cell lymphoma in one and a B cell lymphoma in the
other), exposure to adalimumab was ≤1 year. The total
exposure to anti-TNF therapy and the previous extensive
immunosuppressive treatment for RA together in these
patients represent a risk for the development of lymphoma.
Limitations of our study include the small number of
patients in each subgroup and the nonrandomized study design.
The results of this pilot study indicate that adalimumab
is generally effective and well-tolerated for the treatment of
RA in patients who have failed IFX therapy, including
those who have developed HACA for IFX.
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